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5Introductory note
Three in-depth reviews of topical interest are published as ‘Selected issues’ each year. These Selected issues are based on 
information provided to the EMCDDA by the EU Member States and candidate countries and Norway (participating in the 
work of the EMCDDA since 2001) as part of the national reporting process.
The three issues selected for 2008 are:
Towards a better understanding of drug-related public expenditure in Europe• 
National drug-related research in Europe• 
Drugs and vulnerable groups of young people• 
All Selected issues (in English) and summaries (in 23 languages) are available on the EMCDDA website:
http://www.emcdda.europa.eu/publications/selected-issues
Acknowledgements
The EMCDDA would like to thank the following for their help in producing this Selected issue:
the heads of Reitox national focal points and their staff;• 
the services within each Member State that provided information;• 
the members of the Management Board and the Scientific Committee of the EMCDDA;• 
the Office for Official Publications of the European Communities.• 
Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The network is comprised of national focal points 
in the EU Member States, Norway, the candidate countries and at the European Commission. Under the responsibility of 
their governments, the focal points are the national authorities providing drug information to the EMCDDA.
The contact details of the national focal points may be found at: http://www.emcdda.europa.eu/index.cfm?nnodeid=403 
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7Introduction
Drug-related research is crucial to understanding Europe’s drug problems. Research enables Europe to learn lessons from the 
past, by identifying historical patterns of drug use, and studying the cycles and variations in the problem use of substances. 
Research sharpens Europe’s awareness and monitoring of the present. It provides surveys and data on the scope and scale of 
drug problems, and looks into emerging trends and new patterns in drug use. Research helps Europe to prepare for the future, 
by looking at practical issues such as resource allocation, best practices, the piloting of innovative approaches to managing 
problem drug use. Research is also making great advances in understanding the biological mechanisms involved in addiction 
and how drugs affect the brain, thereby paving the way for new prevention and treatment options. In short, science and 
research enable policymakers to better understand the multiple facets of drug use as it affects both the individual and society.
Today, European drug policy is increasingly ‘evidence-based’. This implies that policy is underpinned by scientific research 
and findings, and that research plays a role in defining policy priorities, best practice and options. Yet building a picture of 
drug-related research in Europe is challenging. Just as drug use cuts across broad sections of society, so drug-related research 
embraces numerous research disciplines, such as public health, psychiatry and psychology, sociology, medicine, law, 
criminology, political science and economics. Drug-related research projects themselves embrace a variety of disciplines and 
methodological approaches, with research on illicit drugs often sharing resources with licit substances such as alcohol, tobacco 
or prescription drugs, or more general concepts of addiction and compulsive behaviours. There are also numerous actors 
involved in drug-related research, from universities and government institutes, through NGOs and think-tanks, to pharmaceutical 
companies and forensic laboratories. Funding for research in Europe is similarly varied — in terms of periodicity and budgetary 
cycles, national, regional or international focus, prioritisation of research objectives, and the multiple sources of financial 
support. Added to this general variety are national, local and regional variations: drug-related research is not evenly distributed 
and available across EU Member States.
So those exploring the territory enter a complex field. Beyond mapping the actors involved in drug-related research, it is also 
important to examine what direct effects research has on decision-making. Again, policy decisions in the area of drug use, as in 
many other areas of governance, are complex. Scientific findings do not always immediately translate into policy. Professional 
practice in areas such as medicine, treatment, social work and law enforcement has it own traditions, structures and constraints, 
and these might delay modifications which reflect the latest research. Nevertheless, both policy and practice increasingly tend 
to listen to science so as to ensure that they can be guided by the most recent knowledge and the implementation objectively 
assessed by all relevant stakeholders.
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Methodology
This Selected issue summarises the available information 
from national focal points and other sources, including the 
EMCDDA’s stakeholders such as its Scientific Committee, 
expert groups, the European Commission, and the Centre’s 
staff. It provides an overview of the framework within which 
drug-related research is carried out in European countries. It 
focuses on a number of topics, including: the role of drug-
related research at national level; coordination and funding 
arrangements; research and dissemination structures; as well 
as major recent research projects. 
In 2007, the EMCDDA’s Reitox network of national focal 
points in 27 Member States, Croatia, Norway and Turkey 
were requested to draft a chapter on drug-related research 
in their country. Responses were received from 25 Member 
States, Croatia, Norway and Turkey (1). This report thus draws 
from the reports provided to the EMCDDA, which may vary 
in scope and coverage, based on availability of resources 
and data at Member State level. The request for information 
covered: 
an overview of national drug-related research structures • 
and policies, in order to understand the role of research in 
national policy, and the focus of national drug research;
a snapshot of current drug-related research within each • 
Member State, in order to investigate the main current 
research areas in the EU, the beneficiaries of research 
funding and the centres of scientific excellence in Member 
States;
a description of national structures and approaches for • 
collecting and disseminating drug-related research results, in 
order to assess the availability of information on drug-related 
research at national level.
Both ‘applied’ and ‘basic’ research were included in 
the reporting exercise (2). Research related to the supply 
reduction field — that is, in the area of criminology, policing, 
enforcement, and seizures— was excluded, as many national 
focal points have limited access to information in this area. 
(1) Data was not available from Bulgaria and Italy, so this report focuses on responses from 25 Member States, plus Croatia, Norway and Turkey.
(2) By ‘applied research’ this report refers to research which is focused on epidemiological studies, specific interventions and policy measures relating to drug use. By 
‘basic research’ this report refers to studies undertaken to acquire new knowledge about drug-related  issues, without any immediate application in view.
Drug-related research and the EU
Drug-related research is recognised as a key element of 
EU drug policy, and is mentioned specifically in two key 
documents defining current drug policy.
The EU drug strategy 2005–12 (1) calls for ‘a 
better understanding of the drugs problem, and the 
development of an optimal response to it through 
a measurable and sustainable improvement in the 
knowledge base and knowledge infrastructure’.
The EU action plan on drugs 2005–08 (2) makes two 
mentions of research:
• Action 43, ‘Promote research in the field of drugs’, 
aims to promote research in the context of the Community 
programme for research and technological development 
— currently managed under the 7th framework 
programme (3) — and of Member States’ own research 
programmes.
• Action 44, ‘Create networks of excellence in drug 
research’, aims at encouraging research networks, 
universities and professionals to develop and create 
networks of excellence for the optimal use of resources, 
together with the effective dissemination of results.
(1) http://www.emcdda.europa.eu/index.cfm?nNodeID=6790
(2) http://www.emcdda.europa.eu/index.cfm?nNodeID=10360 
(3) http://cordis.europa.eu/fp7/ 
The reports from the Reitox national focal points enabled the 
Centre to build an overview of current drug-related research 
in Europe, and to apply a tentative framework of categories to 
classify (i) research actors in Europe, (ii) the broad themes and 
subjects of a corpus of research as reported to the Centre, and 
(iii) available dissemination channels.
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Previous and current EU work on drug-related 
research in Europe
This Selected issue may be viewed as a successor to a 
1996 report, when the EMCDDA was first involved in a 
tentative overview of drug-related research in 15 Member 
States (3) (Kenis, 1996). In 1996, representatives of the 15 
Member States and individual researchers were invited to 
a joint seminar, organised by the European Commission 
and the EMCDDA, entitled ‘Drug research-related initiatives 
in the European Union’. The seminar was held under the 
European Commission’s project Inventing tomorrow which 
aimed to propose guidelines for the Fifth research and 
technical development framework programme. National 
focal points were requested by the European Commission 
Drugs Coordination Unit and the EMCDDA to prepare 
‘national reports on the national drug research situation and 
identification of research needs’ (Kenis, 1996). Thematic 
reports on the ‘Evaluation of action against drug abuse in 
Europe’ (Uchtenhagen, 1996), ‘Research on the medical, 
socio-economic and detection aspects of drug abuse’ 
(DGXII/Irish Presidency 1996) and ‘Criminological research’ 
(Fillieule, 1996) were also prepared.
The 1996 report ‘Research related initiatives in the European 
Union’ (Kenis, 1996) was commissioned by the European 
Commission during the early years of the EMCDDA. It differs 
somewhat in coverage and scope from the present exercise. 
Nonetheless, bearing in mind that, today, almost twice as many 
countries report to the EMCDDA — that is, Member States which 
have joined the EU since 1995, together with third countries — 
the information and recommendations which stemmed from the 
seminar form a baseline against which to assess progress and 
new developments in drug-related research today. This report 
identifies progress in comparison to the available information 
in 1996 and further identifies some limitations and gaps, 
suggesting future developments in this area. 
This Selected issue also precedes further work done in the 
framework of an overview study, A comparative analysis of 
research into illicit drugs in the EU, launched by the European 
Commission’s DG Justice, Freedom and Security (DG-JLS) in 
September 2007 (4). This study will look into the key research 
areas, research disciplines and recent research trends relevant 
to the illicit drug field, covering both drug demand and drug 
supply reduction efforts. The report will look in particular at the 
fulfilment of the objectives of the EU action plan 2005—08 (5). 
This study is due to be published early in 2009. 
(3) At the time: Belgium, Denmark, Germany, Ireland, Greece, Spain, France, Italy, Luxembourg, the Netherlands, Austria, Portugal, Finland, Sweden and the United 
Kingdom.
(4) The tender document for this study is available at: http://ted.europa.eu/Exec?DataFlow=ShowPage.dfl&Template=TED/N_one_result_detail_curr.
htm&docnumber=228475-2007&docId=228475-2007&StatLang=EN
(5) http://www.emcdda.europa.eu/index.cfm?nnodeid=10360
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Drug-related research in national policy
Although continuously present as a topic of policy interest, 
emphasis on drug-related research has not always been 
mentioned as a formal priority across Member States. In 
1996, EU Member States reported that drug-related research 
was considered, by both researchers and policymakers, to be 
‘a very important and relevant topic […] particularly in recent 
years when drug research has experienced a rather dynamic 
development’ (Kenis, 1996). Nevertheless, few links were 
identified between research and drug policy documents. 
Concrete mechanisms for setting priorities in this area 
were referred to as being ‘extremely rare’, and as varying 
from ‘purely scientific considerations to purely political 
considerations, or a mixture of the two’ (Kenis, 1996).
Since 1996, some progress can be reported. Research 
has been introduced into the drug policy documents in 
many European countries. Drug-related research is today 
mentioned in the national drug strategy or action plan of 20 
of the 27 reporting countries, and either merits an entire topic 
to itself in these documents, or is referred to as an essential 
component of evidence-based policy (6). For example, the 
Finnish drug policy 2004—07 stated that research 
knowledge and expertise are indispensable in order to 
effectively plan, evaluate, develop and design drug policy. 
This represents significant progress when compared to the 
situation in 1996, when only two Member States — Ireland 
and the Netherlands — reported specific approaches to 
drug-related research in their national policies (DGXII/Irish 
Presidency, 1996).
Member States which have joined the EU since 2004 have 
reported considerable progress, although some gaps remain. 
The main research efforts mentioned in the Romanian national 
strategy are a general population survey on knowledge, 
attitudes and practices regarding drug use, together with 
a European school project on alcohol and other drugs 
(ESPAD) (7) survey. Similarly, in Estonia, Latvia, and Croatia, 
prevalence studies on drug use in the school and the general 
population, and on problem drug use, are now within the 
scope of national research planning. In Hungary, the national 
drug strategy dedicates a chapter to the importance of 
monitoring, and epidemiological research has mainly been 
conducted in recent years, although research on estimating 
the consequences of drug use is still missing. In Lithuania, the 
national strategy on drug addiction prevention and control 
2004—08 includes scientific research and the development 
of a drugs information system. The Polish national drug 
programme highlights several monitoring and research 
priorities in the area of epidemiology and social responses, 
which include addressing the coverage of drugs in the media, 
and attitudes towards drugs and drug policies.
Many Member States explicitly highlight the need for 
evidence-based policy. In Ireland, the National Drug Strategy 
Review Group concluded that research was essential to 
enable the dissemination of models of best practice in line with 
EU and government policy, and the Irish action plan includes 
commitments to evaluating existing services, and to making 
better use of research findings. The Luxembourg national 
drug action plan 2005—09 explicitly refers to research and 
information as integrated parts of the transversal axes of 
demand and supply reduction. It stresses that research and 
information constitute a primary need for anti-drugs policy. 
Findings from research in the field of drugs are mentioned in 
various Dutch national drug policy documents, with their role 
in underpinning evidence-based drug policy highlighted. In 
Poland, the main objective for research and monitoring in 
this area is to provide information to support implementation 
of the national programme on drugs. In order to reinforce 
the link between research and practice, the Portuguese 
national drugs plan places emphasis on ‘action-research’, 
based on a recommendation of the external evaluation of 
National frameworks for drug-related research
(6) National drug strategies and action plans can be consulted on the EMCDDA website at: http://www.emcdda.europa.eu/?nnodeid=1360
(7) http://www.espad.org
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the 2004 national strategy which noted the lack of focus on 
assessing interventions. The Swedish national drug policy 
emphasises a need to reduce the number of new drug users, 
and as a consequence priority is given to research involving 
the identification of, and prevention within, high-risk social 
groups. The Czech Republic’s national drug strategy mentions 
support of research and the integration of research output into 
practice, and emphasises a need for ‘scientifically verified 
facts and data’. The German Action Plan on Drugs dedicates 
a chapter to research needs, mentioning for example its 
importance in guiding practical applications in areas such as 
early detection and early interventions, secondary prevention, 
and the prevention of relapse. 
Priority-setting is important for matching available funding 
with research needs, and for managing limited resources 
effectively. Member States reported that priorities for drug-
related research in Europe are mainly defined by decision-
makers, and often form part of national strategies or action 
plans. Some countries, such as Belgium and Spain, report a 
‘top-down’ approach, for example where a national research 
programme or strategy includes drug-related research within 
its scope. Countries, such as France and Austria, report 
a ‘bottom-up’ approach, emphasising the importance of 
individual institutions and researchers in setting an agenda 
in the field of drug-related research. While mentioning its 
‘top-down’ approach, Germany also mentions ‘bottom-up’ 
approaches at federal level, and a focus on independence 
among scientific institutions. Finland and Norway stated that 
research priorities are defined based on a dialogue between 
researchers and government.
National drug-related research structures
Universities are the main players in drug-related research in 
Member States. In the medical and treatment fields, much 
research is conducted in university hospitals, for example in 
psychiatric clinics, in faculties of pharmacology and toxicology, 
and in institutes for social medicine and public health. Institutes 
of psychology and education are often involved in drug-related 
prevention research. In the social sciences, the main faculties 
concerned are sociology and criminology, although some 
research is done at forensic institutes or law faculties.
Much drug-related research in Europe is also conducted at 
public research institutes, under the direct or indirect oversight 
of the state. This includes many of the national focal points (8) 
or the institutions that host them, and also national public health 
institutes, national offices for statistics, and national institutes for 
crime and forensic laboratories. Research may in addition be 
conducted in private scientific institutions, not necessarily linked 
to university institutes, which may benefit from public funding, 
for example via commissioned projects.
In total, more than 70 main research structures were cited by 
reporting countries (9). These can be classified into four types 
of structure: (i) academic centres (including universities and 
university linked research centres); (ii) public research centres 
and institutes; (iii) private research centres and institutes (including 
foundations and the pharmaceutical industry); (iv) and institutions 
hosting Reitox national focal points (see Figure 1). As the 
EMCDDA’s national reports in 1996 did not include questions to 
identify the main national structures for drug-related research, it is 
not possible to establish a comparison in this section.
Figure 1: Categorisation of 70 main drug-related research structures reported to the EMCDDA
  Academic
  Public research centres/institutes
  Private research centres/institutes
  National Reitox focal points/host institutions
34 %
22 %
21 %
23 %
(8) http://www.emcdda.europa.eu/index.cfm?nnodeid=403
(9) A complete list is available on the EMCDDA webite, http://www.emcdda.europa.eu/themes/research
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Examples of specialised drug-related research centres in Europe
Centre for Addictology, First Medical Faculty of the Charles University, Prague, Czech Republic. 
http://www.adiktologie.cz
Centre for Alcohol and Drug Research, University of Aarhus, Denmark. 
http://www.crf-au.dk
Centre for Interdisciplinary Addiction Research in Hamburg, Germany. 
http://www.zis-hamburg.de
KETHEA, Greece. 
http://www.kethea.gr
Addiction Research Centre at Trinity College in Dublin, Ireland. 
http://www.socialwork-socialpolicy.tcd.ie/units/addiction.php
Amsterdam Institute for Addiction Research, Netherlands. 
http://www.onderzoekinformatie.nl/en/oi/nod/organisatie/ORG1237472/#lopendprg
Scientific Bureau on Lifestyle, Addition and Related Social Developments (IVO) in Rotterdam, Netherlands. 
http://www.ivo.nl
Ludwig Boltzmann Institute of Addiction Research (LBISucht) in Vienna, Austria. 
http://www.api.or.at/lbi
Institute of Psychiatry and Neurology in Warsaw, Poland. 
http://www.ipin.edu.pl/
Institute of Drug Dependencies at the Centre for the Treatment of Drug Dependencies in Bratislava, Slovakia. 
http://www.drogy.sk/cpldz/idz_e.htm
Centre for Social Research on Alcohol and Drugs (SoRAD) in Stockholm, Sweden. 
http://www.sorad.su.se/
National Addiction Centre in London, UK. 
http://www.iop.kcl.ac.uk/departments/?locator=932
Bergen Clinics Foundation, Norway. 
http://www.bergenclinics.no
Note: This is a non-exhaustive list, provided to illustrate the breadth and range of centres working on drug-related research in Europe. It excludes those based at national focal 
points. The full lists provided for this Selected issue by Member States are available on the Centre’s website at:  
http://www.emcdda.europa.eu/themes/research
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A challenge to quality in research: lack of 
coordination
Well-functioning coordination among researchers, research 
centres and research areas is a prerequisite for continuous, 
comprehensive and high quality research. A serious lack of 
such coordination was already noted by Kenis in 1996. Today, 
this still seems to be a fundamental structural problem in most 
reporting countries, and there is room for improvement with 
regard to cross-disciplinary research. Interdisciplinary, national 
research networks with sustainable funding were reported by 
only a few countries, although the reported initiatives developed 
in recent years have been able to build momentum. In Spain, 
the Addictive Disorders Network (RTA) was set up in 2002 and 
is financed as a network of excellence, embracing 22 research 
groups with a total of 177 researchers. The network aims to 
bring researchers working on basic, clinical and epidemiological 
research closer together. Its features comprise a training 
structure, including a distance training system, and an information 
dissemination system. A German network, consisting of four 
regional networks for research on addictions and covering the 
complete spectrum, from basic research to treatment evaluation, 
received financing from 2000 until 2007. The Polish Society 
for Research on Addictions was set up independently of public 
administration, and aims to promote, initiate and conduct 
interdisciplinary scientific research. In Portugal a drug-related 
research network was recently set up to improve coordination 
and boost synergies amongst researchers in this area. The Nordic 
Centre for Alcohol and Drug Research (NAD), based in Helsinki, 
is a significant player in the Nordic and the Baltic countries. 
NAD promotes and supports research cooperation in the social 
sciences that focuses on the issues of drugs and alcohol. In the 
Czech Republic, ‘addictology’ has been developed using an 
interdisciplinary approach, with a strong research focus. 
In some countries, such as Germany and the UK, multidisciplinary 
societies or associations of drug researchers exist, but more 
often than not, these are discipline-specific, for instance related 
to addiction medicine, psychology or epidemiology. At a 
supranational level, EU-funded research projects are by default 
conducted by multinational networks, and this provides an 
incentive for cross-border collaboration. Researchers in some 
Member States, such as the Netherlands, have experiences of 
strong cooperation with the US National Institute on Drug Abuse 
(NIDA) (10), which is a significant player at the global level in 
funding drug-related research. In addition, various informal or 
semi-formal European networks of researchers exist, and many 
of these already existed in 1996, including the Pompidou 
Group (11) of the Council of Europe (Kenis, 1996). 
Funding arrangements
Drug-related research was already being funded by all the 
reporting Member States in 1996, mainly through public 
agencies (Kenis, 1996). The 1996 report also remarked on 
the positive impact of specific frameworks with earmarked 
funds for drug-related research, as opposed to those operating 
under ‘general heading’ frameworks such as health, social 
sciences, justice etc.). 
Public funding remains the key enabler of drug-related research 
today. Countries reported that funding is typically sourced via a 
range of ministries, for example ministries of science, health, justice, 
social or interior affairs, research, education, defence etc. While 
governments may provide basic funding for some universities and 
research institutes, funds are mostly available through contracts 
for commissioned research or through framework programmes, to 
which researchers apply in open calls for proposals. In national 
framework programmes, drug-related research is usually funded 
under health and social science labels, but drug-related research, 
when funded within these labels might generally receive a 
relatively small proportion of global national research funds. 
Regional authorities and municipalities also play an important role 
in funding drug-related research in many European countries.
In some countries, funding specifically designated for drug-
related research is made available through national drug 
coordination bodies (Czech Republic, Spain, France, Hungary, 
Portugal, Sweden). Other distribution channels include the 
national focal points (Poland, Norway), or specific government 
research programmes in the drugs field, as is the case in Belgium, 
the Netherlands, Slovakia and Finland. Publicly-financed 
foundations also fund drug-related research, and these include 
the Healthy Austria Fund (which funds application-oriented 
research projects, such as project evaluation), the Luxembourg 
National Fund Against Drug Trafficking, the Finnish Foundation 
for Alcohol Studies and the Swedish Council for Working Life 
and Social Research (FAS). Philanthropic foundations are 
also reported as key enablers of research, such as the Joseph 
Rowntree Foundation (12) and the Robertson Trust in the UK or 
(10) http://www.nida.nih.gov/
(11) http://www.coe.int/T/dg3/pompidou/Default_en.asp
(12) The Joseph Rowntree Foundation Drug and Alcohol Research Programme ended in 2005, and currently runs an Alcohol Research Programme.
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the Austrian national bank’s and Swedish national bank’s funds. 
Private organisations are also important, with pharmaceutical 
companies, insurance companies and NGOs providing financial 
backing for research projects. 
At the supranational level, the European Commission provides 
funding for drug research through its framework programmes 
for research and technological development, and through 
specific programmes such as the Public Health Programme 
and the new Drug Prevention and Information Programme. The 
United Nations funds research through UNODC and UNDP. 
Its Global Fund to Fight against HIV/AIDS, Tuberculosis and 
Malaria allocates, for example, funds for different drug-related 
research in Estonia and Romania.
Funding rationales and priorities
Currently, the most frequently reported reason for funding 
or commissioning drug-related research is to produce 
evidence-based knowledge that can be used to underpin 
national policies. In terms of other research rationales, most 
countries set out to establish a sound empirical basis of 
epidemiological research to determine the size and nature of 
drug problems (that is, epidemiological surveys). Assessing 
interventions in the area of drug problems are another key 
reason cited for research. So studies examining the needs of 
different populations in terms of prevention, treatment and, 
more specifically, infectious diseases prevention, are high on 
the agenda. The evaluation of government interventions, in 
terms of effectiveness and cost-effectiveness, are also often 
mentioned, as well as the cost to society of the drugs problem 
and the relationship between drugs and crime. 
Research involving basic research, longitudinal and cohort 
studies, and the ongoing monitoring of drug use that allows for 
the establishment of time trends, are seldom listed as priorities 
by the majority of the reporting countries. However, the regular 
and sustainable funding of such projects is frequently cited as 
being of particular importance, and on this issue there may 
exist a material gap between what policymakers desire at 
the strategy level, and what researchers require, in terms of 
sustainable funding, at the implementation level.
Difficulties in quantifying expenditures on 
drug-related research
Quantifying and describing the expenditure on drug-
related research across countries has proved a difficult 
task for this Selected issue. With regard to the topic of 
national expenditures, only a few Member States, notably 
some of those with more centralised national coordination 
mechanisms, were able to report more detailed information 
on the allocation of funds to drug-related research. These 
were: the Czech Republic, Ireland, Spain, France, Hungary, 
Portugal and Norway. Some Member States were able to 
report on funding for the main research projects (Germany, 
Luxembourg, Malta, Poland and Slovakia) or main research 
funding sources (Finland, the UK). However, for most 
reporting countries, almost no information on drug-related 
research funding was available.
The EMCDDA recently published a Selected issue, Towards 
a better understanding of drug-related public expenditure in 
Europe, and this provides some data on research budgets 
in some countries (EMCDDA, 2008). Among the Member 
States which reported to the EMCDDA on labelled public 
expenditures, six countries indicated funding for research and 
development in 2005, namely Luxembourg, Poland, Slovakia, 
Finland and the UK. They reported expenditure ranging from 
EUR 14 000 on drug-related health research in Slovakia to 
EUR 26 900 000 in general public services drug-related 
research in the United Kingdom (see Table 1). 
Table 1: 2005 reported public expenditures on drug-related research and development in six EU Member States,  
provided for the EMCDDA Selected issue on drug-related public expenditure (EMCDDA, 2008)
Country Year
R&D in general  
public services (EUR)
R&D in health  
services (EUR)
R&D in education 
services (EUR)
Total (EUR)
Ireland 2005 2 072 000 2 072 000
Luxembourg 2005 122 345 122 345
Poland 2005 54 500 54 500
Slovakia 2005 14 000 14 000
Finland 2005 8 000 000 8 000 000
UK   2005* 26 900 000 300 000 1 800 000 29 000 000
(*) UK financial year ending 31 March 2006.
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The fact that only six countries were able to report on this item 
according to the proposed methodology indicates that more 
research on public expenditures and on the impact of drug-
related research is needed.
Limitations and gaps in drug-related research
Defining and categorising drug-related research is a 
complex task. Indeed, the complexity of the field and 
the fact that it straddles various disciplines, may in itself 
constitute a limitation for organising and coordinating 
research at national level, as noted in the Greek national 
report. Classification of research may be done from different 
perspectives, depending on whether the focus is placed 
on disciplines (epidemiology, public health, sociology), 
objectives (basic vis-à-vis applied research), research 
questions (research on patterns of drug use, research on the 
consequences of drug use) or methodologies (quantitative, 
qualitative, experimental, laboratory research). Not 
surprisingly, a number of limitations to drug-related research 
at national level are reported. Issues include: funding 
(insufficient funding, lack of continuity, scattered resources); 
organisation (lack of coordination); training (lack of qualified 
research staff); and methodological aspects (data protection, 
difficulty to reach hidden populations, changes in legal 
regulations). 
Many countries mention that limited available funding is a 
major constraint for drug-related research. This may be due, 
in part, to the fact that funding programmes in health or social 
areas are usually very specific, and are focused on pre-
defined topics. Drug-related research, meanwhile, tends to be 
multidisciplinary and cross-cutting, and it is sometimes difficult 
to fit into funding programmes focused on more rigidly-
defined research segments. In particular, closer integration 
between medical research and the social sciences is required. 
Another challenge linked to funding, and the long-term policy 
impact of research, is a reported lack of continuity in financing. 
Financial restrictions may hamper the possibilities of undertaking 
longitudinal studies, or of repeating national surveys to be 
able to follow a time trend. This is mentioned, for example, by 
Belgium and Latvia. Spain and Portugal have taken account 
of this problem in their drug policy documents, and have 
ensured that funds are earmarked for recurring or longitudinal 
studies. The structural limits faced by drug research also relate 
to short-term, project-related funding. Often, the time needed 
to evaluate results and place study results in context is lacking. 
Subsequent support of practice is often not possible, because 
the researchers involved may have left the research institute after 
a study has been concluded. 
A general concern is the difficulty of attracting young and 
promising researchers to specialise in the field, since long-term 
career prospects may not be guaranteed. Reports from Greece, 
Latvia and Hungary, among others, mention a need for both 
institutionalised training, e.g. graduate and postgraduate studies, 
and further competence enhancement, e.g. through participation 
in international seminars, courses etc.
A recent history of drug-related research in 
Europe
Drug-related research has been around in some shape 
or form in Europe for centuries, and follows the history of 
drug use itself. However, it is useful to sketch some of the 
overriding characteristics of research in recent decades. The 
following overview is neither to be considered authoritative 
or exhaustive, but offers insights into developments in the 
field, and is useful for building a chronology — albeit a 
partial one — of the research topics that have surfaced over 
the past thirty years.
Across EU countries, drug use and drug-related research 
has a long tradition. In the UK, social and criminological 
research into drug epidemiology and related social 
problems began in the 1960s. In parallel, a tradition 
emerged in psychiatry and addiction research (Hartnoll, 
2004). The Netherlands started relatively early with drug-
related epidemiological studies, while Germany has a long 
tradition of treatment research (Kenis, 1996). The Nordic 
countries have a long history of research into alcohol 
and alcohol policy, and since the 1960s illegal drugs 
have also been subject to sociological research (Kenis, 
1996). Notably, the first European methadone study was 
conducted in Sweden in the 1960s (Lenke, Olsson, 1998). 
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Broadly-speaking, illicit drug use came to be seen as 
a visible problem later in most of the other European 
countries, and drug-related research followed 
suit. Nonetheless, France has a strong tradition in 
psychoanalytical drug research, and biomedical 
research has always been significant in Spain (van Lindt, 
1993). Finally, in eastern Europe, drug problems were 
not very prevalent and, at the political level, not fully 
acknowledged before the beginning of the 1990s. In the 
former communist block, ‘narcology’, embracing all forms 
of substance-related problems, emerged as a discipline 
based on the disease model of addiction.
Research related to drug use and drug users took an 
additional, and different tack, with the emergence of HIV 
infection and AIDS in the mid 1980s. Injecting drug users 
were identified as a significant group at risk, both for 
attracting HIV infection and for spreading the virus. Initial 
epidemiological studies in Spain, Italy, the Netherlands 
and Scotland investigated HIV infection among injecting 
drug users, and these were followed by qualitative 
investigations of the social meanings and context of risk 
behaviour and intervention studies (EMCDDA, 2000). 
The risks of HCV infection among the injecting drug user 
population also received attention from researchers at 
a later stage. Today, studies on risk behaviour among 
injecting drug users and other risk groups as regards HIV 
infection have seen a revival in interest in the Baltic states. 
One is a model project on HIV prevention among drug 
users in prisons in the Baltic states, currently being funded 
by UNODC.
Another impetus for drug-related research has been 
the need for effectiveness studies — that is, cost-benefit 
analyses, economic measures, resource allocation studies 
etc. prompted by the scarcity of resources for health and 
welfare. Many of these studies are driven by greater 
demand for effective services and ‘value for money’. 
Evaluative research of interventions are carried out at 
the national or regional level in Member States, where 
the evaluation of treatment services seem to be most 
prominent. In this context, studies on public expenditure on 
drugs attain increasing importance, for instance analysing 
the necessary resources and costs of different forms of 
treatment and imprisonment.
With the development of more refined biomedical 
methodologies, research has advanced substantially in 
recent decades, particularly with regard to studies of 
the brain and the central nervous system, as well as the 
pharmacology, pharmacodynamics and health effects 
of illicit drugs. More sophisticated research is today, 
for example, unravelling the complex cerebral activities 
related to different substances such as alcohol and 
heroin, which act differently to, for example, cocaine 
and amphetamine. The effects of newer synthetic drugs 
such as ecstasy and 2 C-B have also been studied. Much 
research has been devoted to the effects of cannabis on 
the brain as a potentially dependence-inducing substance, 
the relationship between schizophrenia and cannabis 
use, and as a possible medication for specific diseases. In 
addition, the contribution of genetics in terms of addiction 
susceptibility has recently been recognised, and the 
identification of genetic risk factors and genes involved 
in the molecular basis of addiction is a new, and major 
challenge for drug-related research (GENADDICT, 2008).
In summary, reviewing the recent history of drug-related 
research in the EU, we can see some evidence of 
‘sequencing’ taking place. There is a clear tendency for 
initial drug-related research priorities to be linked closely 
to the need for an estimation of the extent of drug use 
at national and regional level, in order to better plan 
interventions and policies. In a second stage, priorities shift 
to applied research, namely as far as needs assessment 
and evaluation of interventions and policies are 
concerned (such as treatment approaches and prevention 
interventions). In this phase, additional qualitative research 
of drug users and their patterns of use complements the 
quantitative epidemiological studies. Finally, in some 
countries, innovative and resource-intensive biomedical 
research has moved into the area of drug effects and 
predisposal.
This research development trend is also visible in other 
parts of the world, for instance in America, where Latin 
American and Caribbean countries, which typically have 
a more recent drug-related research tradition, focus their 
research priorities on epidemiological surveys (Aguilar-
Gaxiola, 2006). The US and Canada, with a longer 
tradition in this area, report a higher investment in applied 
research to evaluate and increase service effectiveness 
and efficiency, as well as basic research (Canadian 
Institutes of Health Research, 2005; National Institute on 
Drug Abuse, 2008).
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Research priorites in some reporting countries
Studies of drug use and attitudes in the school population, 
in particular the European School Survey Project on Alcohol 
and Other Drugs (ESPAD) (13) — a collaborative effort 
of independent research teams in about forty European 
countries and the largest cross-national research project on 
adolescent substance use in the world — have a prominent 
place in all countries. The same holds true for general 
population surveys, although in some countries the regular 
repetition of such surveys has posed funding problems. 
Equally, studies to provide and improve the quality of data 
for the other EMCDDA key indicators generally have high 
priority. These are as follows: the treatment demand indicator, 
drug-related deaths, problem drug use, and drug-related 
infectious diseases. 
A brief listing of developments is helpful in drawing attention 
to recent research priorities in specific reporting countries. 
In Belgium, the focus of drug research since 2001 has • 
been on treatment and on drug-related public nuisance. 
In the Czech Republic, the Ministry of Health research • 
priorities 2007–09 list three areas of particular relevance 
to the drugs field: neurotic and mental illnesses, infectious 
diseases and immunity disorders, and pharmacology and 
pharmaceutics.
Danish drug-related research is user-oriented, and based • 
on assignments given by the authorities wishing to improve 
services and understand the needs of their users. 
In Germany, regional networks cooperated on • 
addiction research, with a focus on examining the provision 
and adaptation of treatment services to address the 
heterogeneous profiles of treatment clients.
In Ireland, research on the relationship between drug • 
use and crime has helped to identify a number of gaps in 
knowledge in this area. Dealing with these gaps is regarded 
as necessary for the development of evidence-based policies 
in both the drugs and criminal justice. 
In Spain, neuroscience research is an important part of • 
the research agenda, and the country invests importantly into 
addiction neurobiology. 
France equally has in the past invested considerable • 
resources into neuroscience. However, it currently spends 60% 
of its funding on the areas of human and social sciences and 
public health, in order to build up and stabilise the research 
potential in this area.
In the Netherlands, the 2006–10 Dutch research • 
programme targets risk behaviour and dependence, focusing 
on behaviour and determinants that characterise addiction. 
The programme aims to identify key factors that influence the 
onset, course and chronicity of substance dependence. 
Portugal reported the need to follow-up, monitor and • 
evaluate services and support decision-making in new areas. 
Sweden has focused research on the identification of high • 
risk groups and tailoring prevention for them, intervention in 
the workplace, and societal and behavioural sciences. 
In the UK, the Blueprint project is the largest drug-related • 
research programme ever run in England and reviews 
evidence on drug-prevention programmes, supplementing 
this with research on teaching and learning practice up to 
curriculum development.
It is interesting that methodological concerns over gaps, 
information availability, research findings dissemination 
and also funding issues made their way into current policy 
documents on drug-related research. This seems to indicate 
a political sensitivity to the need to improve the quality of 
the data and information available, and to promote a sound 
evidence base for decision-making. For example in Ireland, 
a country with a long tradition of drug research, limitations 
on the methods previously used to estimate prevalence are 
recognised, e.g. in the case of the use of treatment data, 
which only reflect those who present themselves for treatment, 
and now research looks into how best to determine the size 
and nature of the drug problem in Ireland. In Luxembourg, 
research on the methodologies for problem drug use 
estimates are considered a research priority.
Zooming in on five main studies in each 
country
In the 1996 study, Kenis reports on observed research 
needs in basically all areas. However, the most pertinent 
need identified was research on prevalence, incidence and 
patterns of drug use and prevention (Kenis, 1996). Research 
into drug policies, treatment, risk factors, aetiology (causes 
and origins) and consequences of drug use, and health 
services was also considered important, but to a lesser 
degree. To gauge the present priorities, the national focal 
points were asked to select and report on five main studies 
(13) http://www.espad.org
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at national level in the last five years. This proved to be a 
difficult exercise for reporting countries, particularly for those 
with a higher number of major ongoing research projects: 
larger countries in particular, with many projects worthy of 
entry, found it difficult to build a meaningful shortlist. Most 
reporting countries selected the projects by size of budget, 
as suggested by EMCDDA guidelines, but other used 
different criteria, for example on the basis of their diversity 
(Austria), relevance to the work of the EMCDDA (Portugal) 
or geographical representation (UK). The overview below 
(Figure 2) provides the results of this shortlisting exercise. 
It is not exhaustive, but it provides an overview of the main 
research projects that are ongoing, or have been recently 
carried out at national level, and it facilitates a basic 
comparison with 1996 reported research needs.
The majority of the reported main projects on drug-related 
research were focused on estimating the prevalence and 
patterns of drug use. Population surveys on prevalence of 
drug use and infectious diseases are the most often cited 
studies, alongside estimates of problem drug use. A basic 
explanation for this result is that these are three of the 
EMCDDA’s key indicators, and thus represent main priorities 
for Reitox national focal points. 22 of the 27 reporting 
countries selected at least one drug use survey as a main 
project at national level, and the ESPAD study of drug use 
prevalence in the school population was the most often 
mentioned epidemiological survey. Thus, the need identified 
as most important in 1996 has been met, although gaps still 
exist in many countries, particularly in terms of funding and 
sustainability of long-term research.
The second area covered by the selected projects is research 
on responses to the drug situation. These are reported from 
western and northern European countries, but also the 
Czech Republic, Greece, Hungary, Austria, Poland, Slovakia 
and Slovenia. This is a broad category, which includes 
the evaluation of interventions (treatment, prevention etc.), 
policies, and the implementation of laws. It also includes 
estimations of public expenditure and economic costs in 
the field of drugs. In 1996, research into interventions 
was considered a priority need by the majority of the 
Member States, and the Kenis report suggested this type 
of research hardly existed at the time, with the exception 
of some evaluative research in the treatment setting. The 
evidence-base in this area has thus expanded considerably, 
although treatment research is still far more predominant than 
prevention research.
The following three areas are much less commonly reported. 
These are: research studies on drug mechanisms and effects 
in France, Lithuania, Slovakia, Austria, Slovenia and Sweden; 
research on the consequences of drug use, reported by 
Denmark, Ireland, Lithuania, Luxembourg, Poland and 
Croatia; and, finally, research on determinants of drug use 
(including risk and protective factors of drug use), in Hungary, 
Malta, Slovakia and Croatia.
Figure 2: Main research projects at national level, classified into five categories
  Research on prevalence, incidence and patterns of drug use
  Research on responses to the drug situation
  Research on determinants of drug use and risk/protective factors
  Research on consequences of drug use
  Research on drug mechanisms and effects
49 %
34 %
3 %
6 %
8 %
Source: Reitox national focal points
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The interface between research, policy and 
practice 
While most national drug strategies and action plans refer to 
the need for evidence-based policies and interventions, the 
link between research results and policymaking is difficult to 
assess. Overall, the vast majority of countries reported that 
research results inform drug policy, at least to some degree. 
A statement by the German national focal point seems to hold 
true for most Member States: ‘just as German policymakers 
have an influence on research by virtue of the statutory 
framework and by funding certain studies, scientific findings 
also contribute to decisions made by policymakers, even if no 
linear relationship is directly perceivable’.
In Finland, the drug policy coordination group regularly listens 
to the latest findings of researchers engaged in drug-related 
research, and research can thus have a direct impact on 
guiding policy. A similar mechanism exists in Norway. The 
Portuguese report confirms a close link between drug-related 
research and policymaking, with national policy determining 
research priorities and consequently funding, and drug-related 
research allowing the follow-up of policy implementation, and 
the design of new policies. 
National reports suggest that research that has been 
commissioned by policymakers has a greater chance of 
being taken into account in decision-making, be it routine 
monitoring, evaluation of specific intervention or policies, or 
when research is initiated to address a specific knowledge 
gap. However, building upon research findings to initiate 
or support policy changes is a complicated process. Many 
players are involved, and cooperation between research, 
politics and practice could be more effective in most countries. 
There are many examples, nonetheless, where research 
and policy are more intimately linked. In Germany, results 
of population surveys reported a considerable increase in 
cannabis use from the 1990s onwards. This has subsequently 
driven policymakers to launch several projects addressing 
cannabis use, particularly among adolescents. In France, 
the drug coordinating MILDT regularly commissions critical 
analyses of available knowledge. These are carried out by a 
multidisciplinary scientific team, assembled for this purpose. 
The authorities thus obtain an objective overview of approved 
knowledge and learn about gaps of knowledge to include 
in future research priorities. In Denmark, general population 
surveys are used in healthcare planning and the prioritisation 
of health promotion and prevention. The evaluation and 
monitoring of research and data collection are often included 
in the political decision-making process, via recommendations 
in evaluation reports, hearings and expert councils. In 
Romania, estimates on problem drug use in Bucharest, 
carried out in 2003 and 2004, indicated that the treatment 
system was under-dimensioned. These estimates led to an 
awareness-raising campaign about heroin use in the city, 
and a legislative framework which facilitates the provision of 
services to heroin users in methadone and syringe exchange 
programmes. Findings from population surveys are used in 
Cyprus for the design of information and awareness-raising 
campaigns and prevention programs although, as yet, 
research has not explicitly been used for policy purposes.
The demand for applied research in national drugs strategies 
is generally seen as a sign that policymakers expect research 
results that can be used to design and restructure existing 
interventions, or to evaluate them. Although research results are 
not always taken into account in the political decision-making 
or in practice, at least not in the short term, there are numerous 
examples of policymaking listening to research results. For 
example, in the Netherlands, indicators which pointed towards 
increasing problematic use of cannabis and cocaine prompted 
preventive measures, and research into effective treatment. 
Another concrete example of research informing drug policy 
is the large National Treatment Outcomes Research Study 
(NTORS) in the UK in the 1990s. This study concluded that 
‘treatment works’, which is now an established principle, and 
which initiated major changes in both the extent and the quality 
of treatment provisions across the UK. 
The Irish national report identifies four specific situations 
in which research projects had very concrete impact on 
policy and practice. These were: a study on treatment of 
under 18s presenting to addiction services; the criteria for 
selecting research into drug use and crime as a priority; the 
use of drug treatment demand data for service availability 
recommendations; and research on family support services.
Occasionally, research results may encounter obstacles, 
where scientific findings are faced with legal, ethical or 
political difficulties during implementation. For example, in 
Germany, research was funded to evaluate the effectiveness 
of diamorphine (heroin) treatment in comparison to 
methadone treatment in a model project. Although heroin 
appeared to be superior to methadone treatment for severely 
dependent drug addicted patients, an application for the 
licensing of diamorphine as a medication eligible for sale 
and prescription has not yet been approved. This would 
require a change in the law by the Federal Parliament. On 
the other hand, the outcomes of a Dutch trial on medical (co-)
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prescription of heroin was directly used by policymakers 
to initiate a permanent provision of this practice for heroin 
addicts who have benefited insufficiently from the currently 
available treatments.
Regionally- and locally-conducted research — for example, 
needs assessment and service evaluation — are typically closer 
to the target of study. As such, their findings may be more 
easily translated into practice. Belgian research projects have 
seen a better success rate in having an impact on practice 
when they have been developed and executed based on 
intensive cooperation with practitioners (e.g. research about 
the treatment chain, and about drug-related policies in 
schools). Another example was reported in Hungary, where 
a prevention programme, Alternatíva, was implemented 
according to the results of a study on the substance use, beliefs 
and prevention needs of youths visiting shopping centres. 
Furthermore, Croatia, with little to report in terms of national 
research initiatives, notes that local-level research initiatives 
have been used for planning prevention activities. 
With regard to basic research — that is, research aimed at 
developing specific scientific knowledge about drugs, drug 
effects and drug use — the relationship between research 
and policy is less evident. Benchmarks for fundamental 
research are by their very nature different from the ones 
used for decision-making and policy. Moreover, very 
few decision-makers in the field of drugs policy have the 
scientific background that would enable them to directly 
understand fundamental research. It was precisely in order 
to tackle such obstacles of explaining scientific findings to 
non-specialists, and summarising the scientific literature, that 
INSERM in France developed its ‘collective expertise’ centre, 
which develops publications  aimed at informing the drug 
coordination authority MILDT and the wider public (14).
Some countries point out the role of science in the 
development of organisational quality standards, human 
resources and training. In the Czech Republic, an evidence-
based approach is applied in the process of certifying the 
professional competence of addiction services. The Spanish 
national plan for scientific research, development and 
technological innovation for 2008–11 places an emphasis 
on generating knowledge and skills oriented towards training 
and hiring highly-qualified staff in both the public and private 
sectors. The Finnish Government’s resolution concerning 
cooperation on drug policy for 2008–11 proposes that 
researcher training and international cooperation of Finnish 
researchers be promoted. Conversely, Denmark reports no 
higher education training related specifically to drug research; 
researchers come from established fields such as psychology, 
law, or medicine, and have often had to make ‘their own 
way’ to establish their expertise within the field. Norway’s 
government plan states that steps should be taken to facilitate 
research, combined with clinical work, and that professionals 
involved in interdisciplinary specialist treatment of addiction 
problems should be able to obtain research leave.
(14) http://www.inserm.fr/fr/questionsdesante/mediatheque/expertises/
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Translating research findings into practice, be it in designing, 
implementing and evaluating interventions or in policymaking, 
has been addressed in many scientific fields and by many 
authors. An important part of this process is making sure that 
appropriate mechanisms are in place to reach all target 
audiences and that they are well-suited to the varying needs 
of the different partners and stakeholders.
In 1996, the Kenis report recorded that ‘mechanisms for 
exchanging research results between researchers’ existed 
in all the 15 EU Member States within the study (Kenis, 
1996). Regular conferences and workshops were reported in 
almost all of these countries. Many of them also reported the 
existence of research networks as an important mechanism 
for sharing research results. At that time, 12 drug research 
scientific journals were listed in 10 of the 15 Member States, 
but no information was available on the number of published 
articles in those or other international scientific journals. The 
existence of the EMCDDA’s Reitox national focal points 
was acknowledged as a positive factor in bringing together 
researchers and policymakers at national level.
In 2007, the 27 reporting countries describe a considerably 
more diversified dissemination infrastructure, which now 
includes a multitude of peer-reviewed and non-peer reviewed 
journals, newsletters and professional magazines, libraries 
and documentation centres, annual national reports, 
dedicated websites, professional and scientific conferences, 
and press conferences, to name those more frequently cited.
Building on the role identified in 1996, institutions hosting 
the Reitox national focal points play an important part in 
disseminating research results in all the reporting countries. 
National focal points’ networks and websites are frequently 
used for disseminating research findings in addition to 
scientific and professional journals. They are also responsible 
for drafting the annual national reports commissioned 
by the EMCDDA (15), and in many cases host libraries 
and documentation centres, publish newsletters, manage 
dedicated websites, link with the media and are involved in 
the organisation of national and international drug-related 
conferences. In particular, NFPs may play a role in ‘making 
sense’ of scientific literature for policymakers, by publishing 
information of a synthetic, summarised nature, such as 
literature reviews and policy briefings. 
Drug-related journals
Dissemination of drug-related research findings is mainly 
achieved through the publication of articles in peer-reviewed 
journals. 27 drug research specialised peer-reviewed journals 
were reported in 2007, more than twice as many as in 1996 
(Kenis, 1996). These journals are mainly published in each 
country’s national language and many have a national focus 
but most publish English abstracts and many of them welcome 
European and international contributions. While most of these 
journals focus on addiction in general, and may include articles 
on alcohol problems, gambling or eating disorders, three of 
them focus more on illicit drug problems (Salud y Drogas, 
Psychotropes and Toxicodependências), three others on more 
specific areas within drugs (Drugs: education, prevention and 
policy, The International Journal of Drug Policy and Mental 
Health and Substance Use: Dual Diagnosis) and one of them 
addresses solely the toxicological dimension of drugs (Annales 
de toxicologie analytique). 
However, distribution of journals is not identical across all 
reporting countries. In fact, only 12 Member States publish at 
least one drug research specialised journal, and more than half 
of the reported journals are concentrated in only four Member 
States (Germany, Spain, France and the UK). The fact that some 
countries do not publish their own drug research specialised 
peer-reviewed journals may indicate a collaborative effort 
Drug-related research dissemination
(15) http://www.emcdda.europa.eu/index.cfm?nNodeID=435 
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amongst different countries. For example, the Nordisk alkohol 
& narkotikatidsskrift (NAT) is a supranational journal, that is 
published in Finland but features articles in Danish, Swedish, 
Norwegian and English and is the main drug-related peer-
reviewed journal in the Nordic countries. However, more often 
it indicates that a significant number of EU countries do not have 
a national drug research specialised journal, in which scientific 
articles can be published in their own language. This might 
be an obstacle to the dissemination of research findings, and 
therefore to their impact in practice and policymaking. 
A higher number of journals may not necessarily facilitate 
better research: there may exist some overlap among 
journals, making tracing the results of research more difficult, 
as researchers compete to be published across a range of 
journals. The visibility of articles within international, typically 
Internet-based, databases may also play a role in the impact 
of research beyond national borders. There may be some 
imbalance between European countries with a longer and 
richer research tradition, and those which are seeking to 
establish a wider audience for their research results. This has an 
impact on the definition of drug-related problems, appropriate 
policies and responses, and the identification and prioritisation 
of research questions and procedures. Some non-English 
drug-related journals offer abstracts in English (see Table 2), 
and this may play a role in making results available to a wider 
public. Yet other factors may come into play, such as whether 
libraries at universities or on a national level subscribe to a 
full – or partial – set of journals. Researchers seeking to conduct 
literature searches ‘without blind spots’ may be helped by 
increased consistency in bibliographic recording, and wider, 
cross-country coverage within bibliographic databases. 
Thus librarianship has a role to play. Emergent specialised 
databases which focus on addiction- and drug-related research, 
may offer researchers better access to information than a more 
general approach using broader scientific databases such as 
PubMed and Web of Science.
Other peer-reviewed journals from a wide array of disciplines, 
ranging from public health to sociology or natural sciences, 
and professional journals, are also important dissemination 
channels for researchers wishing to publish drug-related 
research findings. More than 100 such European journals 
reportedly published drug-related articles in 2006.
For the purposes of this Selected issue, a corpus of journal 
articles and other references, supplied by national focal 
points, was used to assess common themes and topics of 
research. The selection criteria stipulated articles published 
in 2006 by European researchers on illicit drugs. Out 
of 288 classified articles, 65 related to research on 
prevalence, incidence and patterns of drug use; 81 to 
research on responses to the drug situation; 51 to research 
on determinants of drug use and risk/protective factors; 29 to 
research on consequences of drug use; and 62 to research 
on drug mechanisms and effects (Figure 3). 
This corpus of articles suggests that scientific publishing on 
drugs offers a balanced mix of themes and topics. However, 
it also showed a different picture when compared to the 
finding, in the previous section, concerning the distribution by 
categories of the main research projects (Figure 2). Possible 
explanations are a stronger tradition of scientific publishing in 
biomedical and behavioural sciences, coupled with the fact 
that epidemiological studies often are government-funded: they 
are, as such, published as grey literature — mainly reporting on 
statistics, as opposed to analysis and recommendations— and 
may be used more rarely as a basis for scientific articles.
Most of these articles were published in English language 
journals, mainly from the United Kingdom and North 
America. However, many were also published in the 
respective national languages of the country of publication. 
The Netherlands and the United Kingdom lead the list, with 
77 published articles each. The Czech Republic, Belgium, 
Germany, Ireland, Austria, Poland and Portugal, Sweden 
listed between 21 and 10 articles. Estonia, Greece, Lithuania 
and Luxembourg, Hungary, Slovakia, Slovenia, Finland and 
Norway each mentioned 8 articles or fewer. Some countries 
were not able to report on this item, and many reported that 
the information available might not be comprehensive since 
there is no central register of this type of information. Thus the 
corpus of references reported to the EMCDDA is incomplete 
and underestimates the total number of drug-related scientific 
articles published in 2006 by European researchers in 
international peer-reviewed journals.
It is important to note that non-peer reviewed journals and 
professional magazines and newsletters complement peer-
reviewed journals, and also play an important role in all 
countries. This may be particularly the case in those countries 
where peer-reviewed journals are not widely available, or 
drug-related research is still at an earlier stage of development.
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Table 2: Drug research peer-reviewed journals in Europe (16) 
Country of origin Journal Language(s) Website
Czech Republic Adiktologie Czech with English abstracts http://casopis.adiktologie.cz
Germany Addiction Biology English http://www.blackwellpublishing.com/editors.
asp?ref=1355-6215&site=1 
European Addiction Research English http://content.karger.com/ProdukteDB/produkte.asp?A
ktion=JournalHome&ProduktNr=224233
Sucht German with English abstracts http://www.neuland.com/index.php?s=sen&s2=prf 
Suchtmedizin in Forschung und 
Praxis
German with English abstracts http://www.ecomed-medizin.de/sj/sfp/startseite 
Suchttherapie German with English abstracts http://www.thieme.de/fz/suchttherapie/index.html 
Greece Exartisis Greek and English http://www.exartiseis.gr/index.asp
Stigma Greek
Spain Adicciones Spanish http://www.adicciones.es 
Revista Española de Drogode-
pendencias
Spanish http://www.aesed.com/publicaciones.htm
Salud y drogas Spanish, English and French http://inid.umh.es/inicio.asp?mod=revista&ct=portada.
asp
Trastornos Adictivos Spanish http://www.doyma.es
France Alcoologie et addictologie French with English abstracts http://www.sfalcoologie.asso.fr/page.php?choix=B1
Psychotropes French with English abstracts http://www.cairn.info/revue-psychotropes.htm 
Annales de toxicologie analy-
tique
French and English with English 
abstracts
http://www.sfta.org/ATA/ATAintro.html 
Hungary Addiktológia Hungarian with English abstracts http://www.addictologia.hu 
Austria Wiener Zeitschrift für Suchtforsc-
hung
German with English abstracts http://www.api.or.at/wzfs/
Poland Alcoholism and Drug Addiction Polish with English abstracts http://www.ipin.edu.pl/ain/en/aboutus.php 
Portugal Toxicodependências Portuguese with English and 
French abstracts
http://www.toxicodependencias.pt 
Slovakia Alkoholizmus a drogové 
závislosti 
Slovak with English abstracts
Finland Nordisk alkohol & narko-
tikatidsskrift (NAT)
Danish, Norwegian, Swedish and 
English with abstracts in English
http://nat.stakes.fi/EN/nordicstudies.htm
UK Addiction English http://www.addictionjournal.org/ 
Addiction Research and Theory English http://www.tandf.co.uk/journals/titles/16066359.asp 
Drugs: education, prevention 
and policy
English http://www.tandf.co.uk/journals/titles/09687637.html 
The International Journal of 
Drug Policy
English http://www.elsevier.com/wps/find/journaldescription.
cws_home/600949/description 
Mental Health and Substance 
Use: Dual Diagnosis
English http://www.tandf.co.uk/journals/rmhs 
The Journal of Substance Use English http://www.informaworld.com/smpp/title~db=all~ 
content=t713655978~tab=sutmmary
(16)  A list of addiction journals, both in Europe and worldwide, together with submission guidelines and editorial overviews, is provided by the resource list of the International 
Society of Addiction Journal Editors, available at: http://www.parint.org/isajewebsite/isajebook/appendix_a_web.pdf 
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Figure 3: Reported articles published in international peer-reviewed journals in 2006, by category
  Research on prevalence, incidence and patterns of drug use
  Research on responses to the drug situation
  Research on determinants of drug use and risk/protective factors
  Research on consequences of drug use
  Research on drug mechanisms and effects
18 %
27 %
17 %
18 %
20 %
Internet and dedicated websites
In 1996, electronic dissemination channels for drug-related 
research findings such as electronic mailing lists, e-mail or 
dedicated websites did not play a significant role. In 2007 
all reporting countries report the use of electronic channels 
to disseminate results and findings from studies. While, in 
1995, the British Medical Journal (BMJ) was the first general 
medical journal to launch itself in cyberspace (BMJ, 1995) 
and Addiction went online in 1997, today most scientific 
journals are published electronically. Nonetheless, there may 
be a need for awareness-raising about the research tools and 
web databases available to researchers. 
This significant new development shows that stakeholders 
in this field have taken advantage of new communication 
technologies and a wide array of easily accessible websites, 
databases, and portals on drug-related research are now 
available (17). These new dissemination channels make more 
information available to more people in real time and at the 
click of a button. However, it has been suggested that they 
have also promoted an exponential growth of low-quality, 
pseudo-scientific information that is difficult to filter for the 
less knowledgeable public. After a period of enormous 
development and publication in this area, the time may have 
come to think of coordination and validation mechanisms, 
which may in the future add value to the information published 
in these media. 
Other dissemination channels
Libraries and documentation centres are also important means 
for communicating research findings to different audiences. 
Over 40 European alcohol and drug-related documentation 
centres across Europe are organised in European Association 
of Libraries and Information Services on Alcohol and other 
Drugs (ELISAD) (18). In addition, the Greek national focal point 
maintains the Greek Bibliography on Drugs, a collection of 
drug-related scientific papers, published in journals or delivered 
in conferences by Greek experts. Ireland provides a publicly 
available electronic library of Irish drugs research, which 
serves as an important element in the information infrastructure 
supporting research. On its website, the Portuguese national 
focal point provides updated information about drug research 
in Portugal, together with reports of past and current projects. 
Conferences organised by national or regional authorities or by 
professional organisations are important arenas for disseminating 
new knowledge to specific target groups. For example, in the 
Czech Republic, ‘alcohol and toxicomania’ (‘AT’) conferences 
have existed for 47 years. In France clinical psychologists’ 
associations have taken the initiative of organising consensus 
conferences, which focus on therapeutic strategies for specific 
target groups. In the Netherlands, the development of multi-
disciplinary, evidence-based guidelines for good practice have 
proven an important means to disseminate and implement 
research findings. Such guidelines are integrated into professional 
training, with patient versions of guidelines being published, often 
in electronic format. Finally, Reitox national reports, newsletters 
and media relations activities are mentioned as important vehicles 
for disseminating research conclusions.
(17) An extensive list of websites dedicated to disseminating research results in several reporting countries is available at  http://www.emcdda.europa.eu/themes/research
(18) http://www.elisad.eu
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12 years later, where are we now?
The conclusions of the 1996 European Commission– 
EMCDDA joint seminar state that more research was 
needed in a number of areas. These were: drug policies and 
strategies, treatment, risk factors, aetiology , socio-economic 
aspects, supply of drugs, prevalence, incidence and patterns 
of use and prevention. Priority cross-cutting needs were also 
defined, namely: (i) defining research priorities in terms of 
research questions rather than in terms of research disciplines; 
(ii) the value of cross-national and comparative studies; 
(iii) the comparability of research methods and research 
instruments; (iv) the importance of qualitative research;  
(v) the relevance of outcome and cost-effectiveness studies; 
(vi) the role of multi-factorial and therefore multi-disciplinary 
and inter-disciplinary studies. In addition, the conclusions 
also underlined the importance of support structures and 
mechanisms, which were deemed to be crucial for the 
effective implementation of the research needs.
The situation, 12 years later, seems to have developed along 
these lines. 25 EU Member States, Norway, Croatia and 
Turkey are today reporting on drug-related research projects 
and scientific outputs that include all the above areas and 
cross-cutting needs. Most countries also report relatively 
stable support and funding structures at the national level, 
though significant differences exist among them, and concerns 
about funding availability and sustainability are expressed.
The areas which have shown more visible progress in terms 
of research efforts are prevalence, incidence and patterns of 
use: in these areas, all countries now have recent or ongoing 
projects. Other key areas cited include the evaluation of 
interventions (mainly treatment, prevention and drug policies 
and strategies), together with economic aspects of drug 
policy. As for the cross-cutting needs mentioned above, the 
Reitox national focal points currently report national data to 
the EMCDDA using instruments and methods that promote 
data comparability and reliability, and using cross-national 
comparative studies, such as ESPAD. Qualitative research is 
also routinely undertaken by a large number of countries in 
Europe. Furthermore, cost-effectiveness studies were listed as 
a priority by a number of the reporting countries, and a multi- 
and inter-disciplinary approach is generally accepted as a 
means to build understanding of the complex phenomenon 
of drug use and abuse. However, with regard to multi-
disciplinary approaches, concerns were expressed that their 
practical application is not always straightforward or feasible.
The present review also confirms the three-stage ‘sequencing’ in 
the development of national drug-related research which was 
already noted by Kenis in 1996. A political need for drug-
related research stems from a more general desire to set up basic 
indicators for monitoring the drug situation. Thus those countries 
which report a more recent tradition of drug-related research 
mainly focus on epidemiological surveys and indicators, and 
other quantitative methods for estimating drug use. Later, research 
requirements expand to embrace not only to the use of drugs, 
drug-related harm and the study of services, but also to evaluating 
policy and measures. In a third stage, research areas and topics 
may be further diversified to include social, psychological, 
medical and biological mechanisms behind drug use.
Another area which has developed significantly in the past 
decade is the dissemination of research. In comparison to 1996, 
not only did the number of drug research journals increase, 
many of them peer-reviewed, but also new dissemination 
channels, notably those based on the Internet, have developed 
and have made access to research findings easier, quicker and 
available to a wider public. Considerable efforts have been 
made to bridge the gap between research, policy and practice, 
as the evidence-based approach to national strategies and 
action plans demonstrates. Nonetheless, more needs to be done 
to ensure the timely and practical implementation of state-of-
the-art research findings in all the areas and disciplines that 
currently address drug-related research.
Significant limitations and gaps still exist, however. New 
challenges are arising as demands on the evaluation of 
interventions and policy design and implementation are 
Conclusions
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Future developments in drug-related research
Comparing the 1996 and 2007 findings, it is clear that 
the situation concerning drug-related research in Member 
States has developed in a positive way. Nonetheless, 
research must be further consolidated, particularly as regards 
its sustainability, training for young researchers and the 
harmonisation of monitoring instruments. It is hoped that the 
upcoming European Commission-funded study A comparative 
analysis of research into illicit drugs in the EU will enrich this 
overall picture, by providing an in-depth European overview 
with international comparisons, as well as recommendations 
on options for strengthening the drug-related research 
infrastructure in the EU.
One of the major priorities for all types of research seems 
to be knowledge transfer between (i) disciplines within the 
scientific community (ii) science and decision-making, and 
(iii) research and practice. Involving different stakeholders 
in the process of setting priorities for drug-related research 
and — ideally — including them as partners in research 
projects, is likely to encourage this transfer. There is a need 
to finding appropriate mechanisms for regularly updating 
university education and on-the-job training curricula, to reflect 
state-of-the-art research. Other, more practical, tools such as 
synthetic reports targeted to decision-makers, or guidelines for 
practitioners based on the latest scientific evidence, may also 
play a significant role in bridging gaps between research, 
practice and policy. Indeed, such publications of a review 
nature — literature reviews, policy briefings and guidance 
etc. — may play a more important role in translating policy into 
practice than scientific journals alone.
On the other hand, though research into the areas of 
information dissemination and implementation has been 
increasing, more evaluation studies in these areas are 
needed, namely to help ‘clarify the circumstances that 
are likely to modify the effectiveness of a [dissemination] 
intervention’ (Bero 1998). One way forward for overcoming 
limitations and gaps in drug-related research may be to 
promote national research networks, which are dedicated not 
only to disseminating research findings, but also to influencing 
national priorities and organising funding.
As regards future developments in specific areas, the Research 
Platform of the Pompidou Group of the Council of Europe 
recently published two studies on current themes and future 
developments for psychosocial and biomedical drug-related 
research. These suggest, amongst other conclusions, that in 
the area of psychological drug-related research, more studies 
brought to the fore. Funding available for large-scale drug-
related research projects — such as longitudinal studies 
or general population surveys but also important basic 
research — is still limited. Finally, investments in specialised 
university education and research training are needed in most 
countries, in order to attract young researchers to the field. 
A few examples of good practice in European drug-related research
The European School Survey Project on Alcohol and Other Drugs (ESPAD) is a collaborative effort of independent research 
teams and the largest cross-national research project on adolescent substance use in the world. The ESPAD network 
includes about 40 researchers (and their institutions) and is coordinated by the Swedish Council for Information on Alcohol 
and Other Drugs (CAN).
In France, critical analyses of available knowledge are regularly commissioned by MILDT, the national drug coordination 
body, and carried out by multidisciplinary scientific teams. These collective assessment exercises are then presented to the 
French authorities. They encourage the emergence of shared viewpoints and highlight knowledge gaps.
In the Netherlands multi-disciplinary guidelines are developed by using research findings to formulate recommendations for 
good practice or evidence-based work. An implementation committee oversees that these guidelines are used as tools in 
professional training and that their implementation is evaluated.
In Spain, the Addictive Disorders Network (RTA) was set up in 2002 to bring together different types of research and to 
facilitate the use of research results into clinical practice. This network, which also makes drug-related training available, 
currently includes 22 research teams from seven autonomous regions in Spain.
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are needed on the impact of personality traits and pathologies 
related to drug abuse (e.g. impulsivity, sensation-seeking, as 
well as drug expectancies) (Negreiros, 2006). They also 
suggest that physical and psychiatric co-morbidity, ethical 
considerations and academic training should be priorities for 
biomedical drug-related research (Muscat, 2006). 
Other authors have suggested priorities for other research 
disciplines and areas. A recent publication on the 
epidemiology of drug abuse (Sloboda, 2005) suggests that 
research is needed to help clarify how distant, longer-term 
factors may affect closer, shorter-term factors that influence 
substance use or abuse. This publication also argues that 
the promotion of multidisciplinary approaches and the 
harmonisation of concepts and methodologies also be listed 
priorities for future drug-related research. Another recent 
study (Nowotny, 2005) discusses research concerns at 
a more general level: future priorities in applied research 
might be influenced by identified trends in general research. 
These may include: an increased attempt of steering 
research priorities at supranational and national levels 
(e.g. the influence of the EU and/or national strategy and 
action plans on drugs on research priorities); the increased 
commercialisation of research (such as funding by the 
pharmaceutical industry in specific research areas); and the 
increased accountability of science through efforts to evaluate 
its effectiveness and assess its quality.
However, only a limited number of publications exist of a 
forward-looking or prescriptive character with regard to drug-
related research. There may be other areas where research 
efforts might be strengthened. These include, for example, the 
increased availability of research into criminology and the 
law enforcement area; analysis of long-term developments in 
drug use, especially research which leverages non-subjective 
sampling, ever-improving sets of historical data and a gradual 
shift towards more cross-national studies.
Diversity may be a strength for European research. The 
existence of different types of research approaches across 
different Member States, or within specific Member States, 
can stimulate creativity and diversity in research, and 
may lead researchers to discover new approaches, or to 
question long-held assumptions. The more different types of 
research and research approaches are combined, the more 
comprehensive insights will be possible in understanding drug 
use and its consequences. 
Tactical efforts channelled into specific areas may prove 
successful. Promotion of coordination, and the dissemination 
of information in an appropriate format, are vital. In order to 
build on investments made in the past, and to retain talent and 
expertise, goodwill is currently needed to ensure that research 
is planned, and financed, that is to be sustainable well into the 
future. Finally, a multidisciplinary approach, one that is able 
to engage researchers and stakeholders across ministerial, 
academic or country borders, must be a priority.
Regular overviews and monitoring of drug-related research, 
based on more harmonised data, may be helpful in keeping 
all stakeholders informed on future developments in the area 
and in identifying limitations, gaps and priorities for the future. 
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one 
of the European Union’s decentralised agencies. Established in 1993 and based 
in Lisbon, it is the central source of comprehensive information on drugs and drug 
addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, reliable and 
comparable information on drugs and drug addiction. In doing so, it provides its 
audiences with an evidence-based picture of the drug phenomenon at European level.
The Centre’s publications are a prime source of information for a wide range of 
audiences including policymakers and their advisors; professionals and researchers 
working in the field of drugs; and, more broadly, the media and general public.
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